Idiopathic Intracranial Hypertension (IIH)
IIH (pseudotumor cerebri) is characterized by elevated intracranial pressure without mass lesion or hydrocephalus. It predominantly affects women with obesity of childbearing age. Goals are headache relief and preservation of visual function.
Symptoms
- Daily diffuse headaches, worse with Valsalva or lying down
- Transient visual obscurations, blurred vision
- Pulsatile tinnitus
- Diplopia (6th nerve palsy)
- Papilledema on fundus examination
Diagnosis
- MRI/MRV to rule out mass, venous sinus thrombosis; features include empty sella, posterior scleral flattening
- Lumbar puncture opening pressure ≥25 cm H₂O with normal CSF composition
- Ophthalmologic evaluation: visual acuity, visual fields, OCT of retinal nerve fiber layer
- Check for secondary causes (drugs like tetracyclines, vitamin A excess, endocrine disorders)
Management
Weight Management
- 5–10% weight loss can normalize intracranial pressure
- Bariatric surgery for refractory obesity-associated IIH
Medical Therapy
- Acetazolamide first-line to reduce CSF production (target up to 1–4 g/day as tolerated)
- Topiramate alternative (also aids weight loss)
- Headache adjuncts: migraine preventives, lifestyle changes
Procedural/Surgical
- Serial lumbar punctures for temporary relief
- Optic nerve sheath fenestration to protect vision
- CSF shunting (ventriculo- or lumboperitoneal) for refractory cases
- Venous sinus stenting for confirmed venous outflow obstruction (selected patients)
Monitoring
- Regular ophthalmology visits (visual acuity, fields, OCT)
- Assess for medication side effects (paresthesia, kidney stones, metabolic acidosis)
- Address comorbid migraine, sleep apnea
Living with IIH
- Track headaches, vision changes, medications, weight, sleep, triggers, ophthalmology appointments
- Use low-salt diet, stay hydrated, avoid vitamin A supplements
- Manage anxiety/depression; chronic headaches and vision fear are taxing
- Plan pregnancy with neurologist (IIH can worsen during pregnancy; acetazolamide risk/benefit individually assessed)
Complications
- Permanent vision loss from chronic papilledema
- Shunt malfunction/infection
- Medication side effects (kidney stones, metabolic acidosis, cognitive slowing)
Research & Future Directions
GLP-1 agonists, venous stent trials, digital ICP-monitoring wearables, and precision headache therapies are under study.
Experimental & Emerging Treatments
- GLP-1 Receptor Agonists: Weight loss + potential CSF-lowering effects (liraglutide, semaglutide) in trials.
- Digital Ocular Monitoring: Home OCT and visual field apps for rapid detection of papilledema changes.
- Novel Carbonic Anhydrase Inhibitors: Agents with fewer paresthesias and renal risks.
- Endovascular Sinus Stents with Pressure Sensors: Provide feedback on venous gradients to guide therapy.
Track IIH with Diagnoza.care
Protect Your Vision, Calm the Pressure – Log headaches, visual symptoms, medications, weights, sleep patterns, ophthalmology findings, lumbar punctures, and procedures; capture side effects; and let the AI companion remind you of visual field tests and lifestyle goals.
Medical Disclaimer: Informational only. Work with your neurologist/neuro-ophthalmologist for diagnostic confirmation, medication dosing, weight-loss planning, and surveillance.
Sources: Intracranial Hypertension Research Foundation, American Academy of Neurology, European Headache Federation